Gastric polyp Medical Services in China

Gastric polyps are localized, benign mucosal protrusions arising from the stomach lining. They are typically discovered incidentally during upper gastrointestinal endoscopy performed for unrelated symptoms such as dyspepsia, anemia, or surveillance. While most gastric polyps are asymptomatic and non-neoplastic, their clinical significance lies in their heterogeneous histopathology—primarily classified as hyperplastic polyps (60–80%), fundic gland polyps (10–30%), and adenomatous polyps (<10%). Adenomatous polyps carry the highest malignant potential, with risk of progression to gastric adenocarcinoma increasing with size (>2 cm), dysplasia grade, and presence of intestinal metaplasia. Pathogenesis varies by type: hyperplastic polyps are strongly associated with chronic atrophic gastritis and Helicobacter pylori infection, leading to mucosal injury and regenerative hyperplasia; fundic gland polyps are often linked to long-term proton pump inhibitor (PPI) use or familial adenomatous polyposis (FAP); adenomatous polyps arise from neoplastic transformation of gastric epithelium, frequently in the context of chronic inflammation, bile reflux, or genetic predisposition. Epidemiologically, gastric polyps are detected in 1–6% of routine upper endoscopies in adults, with prevalence rising sharply after age 50. Hyperplastic polyps predominate in older women and individuals with H. pylori-related gastritis, while fundic gland polyps are more common in middle-aged women on chronic PPI therapy. Risk factors include persistent H. pylori infection, autoimmune gastritis, long-term PPI use (>1 year), smoking, high-salt diet, and genetic syndromes such as FAP or Lynch syndrome. Although most patients remain asymptomatic, larger or multiple polyps may cause occult gastrointestinal bleeding (leading to iron-deficiency anemia), epigastric discomfort, nausea, or, rarely, gastric outlet obstruction. Quality of life impact is generally low for small, non-dysplastic polyps under surveillance; however, patients face psychological burden from cancer anxiety, repeated endoscopic monitoring, dietary restrictions, and medication adjustments. Those requiring polypectomy or surgical resection experience short-term procedural recovery, potential complications (e.g., bleeding, perforation), and long-term surveillance obligations—impacting work productivity, travel, and healthcare engagement. Timely diagnosis via high-definition endoscopy with chromoendoscopy or narrow-band imaging, coupled with targeted biopsy and histopathologic classification, is essential to guide risk-stratified management and prevent unnecessary interventions or missed malignancy.

Gastric polyps are discrete mucosal protrusions within the stomach lumen, typically identified incidentally during upper gastrointestinal endoscopy. They are histologically heterogeneous and broadly classified into neoplastic (e.g., adenomas) and non-neoplastic (e.g., fundic gland polyps, hyperplastic polyps, hamartomatous polyps) subtypes—each with distinct etiologies and clinical implications. Common causes include chronic mucosal injury and aberrant epithelial proliferation driven by persistent inflammatory or hormonal stimuli. Fundic gland polyps (FGPs), the most prevalent type (accounting for ~75% of gastric polyps), arise from cystic dilation of fundic glands and are strongly associated with long-term proton pump inhibitor (PPI) use—likely due to PPI-induced hypergastrinemia, which stimulates parietal and chief cell proliferation. Hyperplastic polyps (15–20% of cases) result from chronic gastritis, particularly autoimmune or Helicobacter pylori-associated atrophic gastritis; they reflect regenerative epithelial hyperplasia in response to sustained inflammation, oxidative stress, and impaired mucosal repair. Gastric adenomas (5–10%) are true neoplasms arising from dysplastic transformation of gastric epithelium, almost invariably occurring in the setting of intestinal metaplasia—a precancerous change commonly triggered by longstanding H. pylori infection or chronic bile reflux.

Triggers encompass both pharmacologic and physiologic perturbations. PPI therapy exceeding one year significantly increases FGPs incidence in a dose- and duration-dependent manner. Acute or recurrent gastric mucosal injury—such as from NSAID use, alcohol-induced erosions, or endoscopic biopsy trauma—may initiate localized hyperproliferative responses that evolve into hyperplastic polyps. Bile reflux following gastrectomy or pyloric dysfunction induces chronic chemical injury, promoting metaplasia and subsequent adenoma formation. Additionally, abrupt withdrawal of high-dose PPIs may unmask latent polyps previously obscured by acid suppression-related mucosal edema.

Established risk factors include age (>50 years), female sex (particularly for FGPs), and chronic gastric inflammation. H. pylori infection remains the predominant environmental risk factor for hyperplastic and adenomatous polyps; its virulence factors (CagA, VacA) induce DNA damage, inhibit apoptosis, and disrupt cell cycle regulation. Atrophic gastritis—whether autoimmune (anti-parietal cell antibodies, low pepsinogen I/II ratio) or environmental—confers elevated risk for both hyperplastic and adenomatous polyps due to loss of acid-secreting mucosa and compensatory hypergastrinemia. Prior gastric surgery (e.g., Billroth II reconstruction) increases adenoma risk via stasis, bacterial overgrowth, and bile reflux. Smoking is independently associated with larger, multiple, and dysplastic hyperplastic polyps, likely through nicotine-mediated angiogenesis and oxidative DNA adduct formation.

Genetic factors play a critical role in specific syndromes. Familial adenomatous polyposis (FAP), caused by germline APC gene mutations, predisposes to gastric adenomas—particularly fundic gland polyps with dysplasia—and confers up to 50% lifetime risk of gastric adenocarcinoma. Peutz-Jeghers syndrome (STK11/LKB1 mutations) features hamartomatous gastric polyps with malignant potential. Hereditary diffuse gastric cancer (CDH1 mutations) rarely presents with polyps but may show early signet-ring cell foci mimicking polypoid lesions. More recently, somatic mutations in CTNNB1 (β-catenin), KRAS, and TP53 have been implicated in sporadic adenoma progression, while FGPs frequently harbor activating mutations in the Wnt pathway regulator RNF43—especially in PPI-unexposed patients, suggesting intrinsic genetic susceptibility.

Environmental exposures beyond H. pylori include dietary nitrosamines (from smoked/cured meats), low antioxidant intake (vitamin C, E, selenium), and occupational exposure to asbestos or rubber manufacturing chemicals—each linked to increased oxidative gastric mucosal damage and polyp carcinogenicity. Socioeconomic factors such as poor sanitation and crowded living conditions correlate with earlier and more severe H. pylori acquisition, thereby amplifying polyp risk across generations. Finally, metabolic syndrome components—including obesity, insulin resistance, and chronic low-grade systemic inflammation—promote gastric epithelial proliferation via IGF-1 upregulation and IL-6–mediated STAT3 activation, contributing to polyp initiation and growth. Comprehensive risk stratification thus requires integration of endoscopic morphology, histopathology, serologic markers (gastrin, pepsinogens, anti-H. pylori IgG), genetic counseling where indicated, and longitudinal surveillance per international guidelines (e.g., ACG, ESGE).

Gastric polyps are discrete, localized mucosal protrusions arising from the gastric epithelium or submucosa. They are predominantly asymptomatic and often discovered incidentally during upper gastrointestinal endoscopy performed for unrelated indications. However, symptomatology—when present—varies significantly depending on polyp size, histologic subtype (e.g., hyperplastic, fundic gland, adenomatous, hamartomatous), anatomic location (fundus, body, antrum, pylorus), and presence of complications. Early symptoms are typically subtle and nonspecific; many patients remain entirely asymptomatic even with polyps measuring 1–2 cm. When early manifestations occur, they may include intermittent epigastric discomfort described as dull, pressure-like, or mild burning—distinct from classic peptic ulcer pain in its lack of clear temporal relationship to meals or nocturnal awakening. Some individuals report transient postprandial fullness or early satiety without objective evidence of gastric outlet obstruction. Mild, self-limited nausea may be noted, particularly after fatty meals, but vomiting is exceedingly rare at this stage. Importantly, early symptoms do not correlate reliably with polyp burden or malignant potential; small adenomas may be silent while large hyperplastic polyps remain asymptomatic.

Typical symptoms emerge with increasing polyp size (>2 cm), multiplicity, or anatomically strategic positioning (e.g., near the pylorus or cardia). The most common clinically apparent presentation is chronic, occult gastrointestinal bleeding, evidenced by iron-deficiency anemia (microcytic, hypochromic) in the absence of overt melena or hematemesis. Patients may report fatigue, pallor, exertional dyspnea, or palpitations secondary to anemia—often the first clue prompting diagnostic evaluation. Overt bleeding occurs less frequently but manifests as coffee-ground emesis (indicating upper GI hemorrhage with gastric acid exposure) or melena; hematemesis is uncommon unless the polyp is ulcerated, friable, or located in proximity to major vasculature. Larger pedunculated polyps may undergo torsion or intussusception, leading to episodic colicky epigastric pain, nausea, and non-bilious vomiting—mimicking biliary or pancreatic colic. Gastric outlet obstruction, though rare, can occur with giant polyps (>4 cm) or clusters in the antrum/pylorus, presenting with progressive postprandial vomiting (often containing undigested food), significant weight loss, and visible gastric peristalsis.

Accompanying symptoms reflect underlying pathophysiology or comorbid conditions. Chronic gastritis—particularly autoimmune or H. pylori-associated—is frequently associated with fundic gland polyps (FGPs) and hyperplastic polyps, respectively; thus, patients may concurrently exhibit symptoms of gastritis: epigastric burning aggravated by NSAIDs or alcohol, mild anorexia, or halitosis. In familial adenomatous polyposis (FAP), gastric polyps (usually FGPs or adenomas) coexist with duodenal adenomas and colorectal polyposis; patients may report a family history of early-onset colorectal cancer, desmoid tumors, or congenital hypertrophy of the retinal pigment epithelium (CHRPE). Patients with Peutz-Jeghers syndrome may present with mucocutaneous pigmentation and recurrent abdominal pain due to intestinal intussusception, alongside gastric hamartomatous polyps. Dyspepsia—defined per Rome IV criteria as persistent or recurrent pain or discomfort centered in the upper abdomen—may be reported, but it is not specific and overlaps substantially with functional dyspepsia; therefore, polyps should not be presumed causative without endoscopic confirmation.

Complications arise infrequently but carry clinical significance. Malignant transformation is the most consequential complication, occurring almost exclusively in adenomatous polyps (dysplasia-carcinoma sequence), with risk escalating with size (>2 cm), high-grade dysplasia, villous architecture, and sessile morphology. Carcinoma-in-situ or invasive adenocarcinoma may develop silently; symptoms then reflect advanced gastric malignancy—persistent anorexia, profound weight loss (>10% body weight), persistent vomiting, or palpable epigastric mass. Ulceration of large or inflamed polyps can precipitate acute upper GI hemorrhage, requiring urgent endoscopic intervention. Polyp-related obstruction may lead to gastric stasis, bacterial overgrowth, and malnutrition. Rarely, pedunculated polyps prolapse through the pylorus into the duodenum, causing intussusception or mechanical ileus. Spontaneous polyp detachment may result in transient hematochezia if distal transit occurs, though this is atypical.

Diagnosis relies primarily on high-definition white-light endoscopy (HD-WLE), which allows real-time assessment of size, morphology (pedunculated vs. sessile), surface pattern, color, and vascular architecture. Chromoendoscopy (indigo carmine or acetic acid) and magnification endoscopy enhance detection of subtle dysplastic changes. Biopsy is mandatory for all polyps >5 mm and for any polyp with suspicious features (e.g., irregular surface, erythema, ulceration, spontaneous bleeding); histopathologic analysis determines subtype, grade of dysplasia, and margins. Endoscopic ultrasound (EUS) is indicated for large (>2 cm), submucosal-appearing, or indeterminate lesions to assess depth of invasion and exclude deeper malignancy. Serologic testing for H. pylori (urea breath test, stool antigen) and serum gastrin levels (to evaluate for Zollinger-Ellison syndrome in cases of multiple FGPs) provide adjunctive etiologic insight. Genetic testing is warranted when clinical suspicion for hereditary syndromes exists (e.g., APC gene testing in FAP).

Differential diagnosis includes other gastric mucosal abnormalities that mimic polyps endoscopically. Gastric adenocarcinoma may present as a sessile, ulcerated, or exophytic mass—distinguished by irregular borders, nodularity, and friability; biopsy is definitive. Gastrointestinal stromal tumors (GISTs) arise from the muscularis propria, often exhibiting submucosal bulging with central umbilication; EUS confirms extramucosal origin. Lymphoid follicular hyperplasia appears as numerous small, pale, round nodules—typically antral and associated with chronic H. pylori infection. Eosinophilic gastroenteritis may cause diffuse mucosal edema and nodularity but lacks discrete polypoid architecture. Metastatic lesions (e.g., from melanoma or lung cancer) are exceedingly rare but must be considered in patients with known malignancy and multiple, atypical gastric lesions. Non-neoplastic mimics include retained food debris, mucus caps, or endoscopic artifacts—differentiated by irrigation, suction, or gentle probing. Crucially, functional dyspepsia and chronic gastritis lack endoscopic structural correlates; their diagnosis is one of exclusion after negative endoscopy and appropriate testing.

Gastric polyps are mucosal protrusions within the stomach lumen, typically discovered incidentally during upper gastrointestinal endoscopy. They represent a heterogeneous group of lesions with varying histopathological features, biological behaviors, and malignant potential. Accurate classification—primarily into hyperplastic polyps (most common, low malignant risk), fundic gland polyps (often associated with proton pump inhibitor use or familial adenomatous polyposis), and adenomatous polyps (premalignant, with documented progression to gastric adenocarcinoma)—is essential for guiding management. Treatment strategy is individualized based on polyp size, number, morphology, histology, patient age, comorbidities, and surveillance feasibility.

Conservative treatment is appropriate for small (<5 mm), asymptomatic, non-adenomatous polyps—particularly solitary hyperplastic or fundic gland polyps without dysplasia. In such cases, observation with scheduled endoscopic surveillance is preferred over intervention. Surveillance intervals depend on histology and risk profile: patients with sporadic hyperplastic polyps <10 mm and no dysplasia generally require repeat gastroscopy in 3–5 years; those with multiple (>20) or larger (>10 mm) hyperplastic polyps may warrant more frequent monitoring (every 1–2 years) due to slightly elevated neoplastic risk. Conservative management also includes addressing underlying drivers—such as eradicating Helicobacter pylori infection (a known contributor to chronic gastritis and hyperplastic polyp formation) and discontinuing long-term proton pump inhibitors when clinically feasible in patients with fundic gland polyps. Lifestyle modifications—including smoking cessation, moderation of alcohol intake, and dietary optimization (increased fruits/vegetables, reduced salted/preserved foods)—are recommended to mitigate chronic gastric inflammation and oxidative stress.

Pharmacologic therapy plays a supportive rather than definitive role. There are no FDA- or EMA-approved drugs specifically for gastric polyp regression. However, H. pylori eradication regimens (e.g., bismuth quadruple therapy or clarithromycin-based triple therapy, tailored per local antibiotic resistance patterns) significantly reduce recurrence of hyperplastic polyps and improve gastric mucosal health. In patients with autoimmune gastritis-associated fundic gland polyps, high-dose vitamin B12 supplementation may be indicated but does not affect polyp burden. For patients with familial adenomatous polyposis (FAP), chemoprevention with sulindac or celecoxib has shown modest reduction in duodenal polyp burden but lacks robust evidence for gastric efficacy and is not routinely recommended for isolated gastric polyps. Proton pump inhibitors remain first-line for symptom control in patients with concomitant GERD or erosive gastritis but should be used at the lowest effective dose and duration to avoid potential polyp proliferation.

Surgical treatment is rarely required for gastric polyps but becomes necessary in specific scenarios. Endoscopic resection is the primary therapeutic modality—not surgical gastrectomy—for most polyps ≥6 mm, all adenomatous polyps regardless of size, and any polyp exhibiting suspicious features (e.g., nodularity, ulceration, rapid growth, or surface irregularity). Techniques include cold snare polypectomy (for polyps <10 mm without dysplasia), hot snare polypectomy, endoscopic mucosal resection (EMR) for flat or laterally spreading lesions up to 20 mm, and endoscopic submucosal dissection (ESD) for larger (>20 mm), complex, or recurrent adenomas where en bloc resection and precise histopathologic assessment are critical. Surgical gastrectomy (subtotal or total) is reserved for rare cases: multifocal high-grade dysplasia unamenable to endoscopic clearance, invasive carcinoma confirmed in a polyp, or diffuse gastric polyposis with uncontrollable bleeding or obstruction. Laparoscopic-assisted or robotic-assisted resections are increasingly utilized in tertiary centers for select cases requiring surgical intervention, offering improved precision and faster recovery versus open surgery.

Treatment in China offers distinct advantages rooted in infrastructure, expertise, and integration. China hosts the world’s largest volume of upper GI endoscopies annually, fostering unparalleled operator experience—especially in advanced resection techniques like ESD. Major academic centers (e.g., Zhongshan Hospital Fudan University, Peking Union Medical College Hospital) maintain standardized national guidelines aligned with ACG and ESGE recommendations while incorporating real-world data from Chinese cohorts. Rapid adoption of AI-assisted endoscopic imaging (e.g., real-time histology prediction via narrow-band imaging + deep learning algorithms) enhances detection and characterization accuracy. Furthermore, China’s centralized pathology networks enable expedited, high-fidelity histologic interpretation with molecular subtyping (e.g., mismatch repair protein immunohistochemistry) when indicated. Cost-effectiveness is notable: endoscopic resection costs approximately 30–50% less than comparable procedures in Western Europe or North America, with minimal out-of-pocket expense under national health insurance for eligible indications. Multidisciplinary tumor boards integrating gastroenterologists, pathologists, oncologists, and surgeons ensure coordinated decision-making for high-risk cases.

Post-treatment recovery emphasizes safety, surveillance, and mucosal healing. Patients undergoing endoscopic resection should observe a clear-liquid diet for 6–12 hours post-procedure, advancing to soft bland foods over 2–3 days; NSAIDs and anticoagulants must be withheld per protocol (typically 5–7 days) unless bridging strategies are implemented. Vigilance for delayed complications—such as post-polypectomy bleeding (occurs in ~1–3% of EMR/ESD cases) or perforation (<0.5%)—is critical; symptoms including hematemesis, melena, or acute abdominal pain warrant immediate evaluation. Follow-up endoscopy is mandatory: for complete EMR/ESD specimens, a control exam at 3–6 months confirms clearance and assesses for residual or recurrent disease; thereafter, surveillance intervals are stratified by final histology (e.g., low-grade dysplasia: every 1–3 years; high-grade dysplasia: every 6–12 months until stable). Long-term gastric health maintenance includes annual serum pepsinogen I/II ratio and gastrin-17 testing in patients with atrophic gastritis or intestinal metaplasia, periodic H. pylori retesting if initially positive, and avoidance of chronic irritants (smoking, excessive alcohol, habitual NSAID use). Nutritional counseling focusing on antioxidant-rich foods and micronutrient sufficiency (vitamin C, selenium, folate) supports epithelial integrity and reduces oxidative DNA damage. Psychological support is encouraged, particularly for patients with FAP or high-grade dysplasia, to address anxiety related to cancer risk and surveillance burden.